Global biosimilar market to grow to US$3.7 billion in 2015

Biosimilars/General | Posted 08/04/2011 post-comment0 Post your comment

According to a report by Datamonitor published on 23 February 2011 the global biosimilars market will grow from US$243 million in 2010 to US$3.7 billion in 2015.

picture 67

In 2009, the combined biosimilars market size for the US and five major European markets was a mere US$150 million. The positive forecast by Datamonitor for 2015 is mainly based on the fact that between 2011 and 2015 more than 30 branded biologicals with sales of US$51 billion will lose their patent exclusivity.

The market analyst company believes that ‘due to their complexity, cost, and development risks’ biosimilar production will be limited to ‘only a handful of pharma companies, all of which are established generics players’. Although electronics giant, Samsung, has perhaps not listened to this advice—with their biosimilars deal with Quintiles announced on 28 February 2011.

Drivers for growth in the biosimilars market include the growing use of biologicals, and the need for more cost-effective treatments. However, there remain a large number of barriers, not least of which is the lack of guidance for the implementation of the biosimilars pathway in the US.

Related articles

Samsung to enter biosimilars market

US biosimilars pathway unlikely to be used

US guidelines for biosimilars

Source: Datamonitor

comment icon Comments (0)
Post your comment
Related content
EMA calls for biosimilar interchangeability across the EU
01 AA007239
Biosimilars/General Posted 23/09/2022
Overview of monoclonal antibody biosimilars in Latin America
Biosimilars/General Posted 17/06/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010